SEARCH

SEARCH BY CITATION

References

  • 1
    Baynes JW, Thorpe SR. Role of oxidation stress in diabetic complications. A new perspective on an old paradigm. Diabetes 1999; 48: 19.
  • 2
    Davì G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, Pennese E, Vitacolonna E, Bucciarelli T, Costantini F, Capani F, Patrono C. In vivo formation of 8-iso-prostaglandin F2α and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999; 99: 2249.
  • 3
    Lawson JA, Rokach J, FitzGerald GA. Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. J Biol Chem 1999; 274: 244414.
  • 4
    Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscl Thromb Vasc Biol 1997; 17: 230915.
  • 5
    Fu MX, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW. Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes 1994; 43: 67683.
  • 6
    Uchida K, Kanematsu M, Sakai K, Matsuda T, Hattori N, Mizuno Y, Suzuki D, Miyata T, Noguchi N, Niki E, Osawa T. Protein-bound acrolein: potential markers for oxidative stress. Proc Natl Acad Sci USA 1999; 95: 48827.
  • 7
    Rota S, McWilliam NA, Baglin TP, Byrne CD. Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation. modulation by oxidation and vitamin E. Blood 1998; 91: 50815.
  • 8
    Weinstein EA, Li H, Lawson JA, Rokach J, FitzGerald GA, Axelsen PH. Prothrombinase acceleration by oxidationly damaged phospholipids. J Biol Chem 2000; 275: 2292530.
  • 9
    Shacter E, Williams JA, Levine RL. Oxidation modification of fibrinogen inhibits thrombin catalyzed clot formation. Free Rad Med Biol 1995; 18: 81521.
  • 10
    De Cristofaro R, Landolfi R. Oxidation of human α-thrombin by the myeloperoxidase–H2O2–chloride system: structural and functional effects. Thromb Haemost 2000; 83: 2536111.
  • 11
    Oates AM, Salem HH. The binding and regulation of protein S by neutrophils. Blood Coagul Fibrinol 1991; 2: 6017.
  • 12
    Stief TW, Aab A, Heimburger N. Oxidation inactivation of purified human alpha-2-antiplasmin, antithrombin III, and C1-inhibitor. Thromb Res 1988; 49: 5819.
  • 13
    Durand P, Prost M, Loreau N, Lussier-Cacan S, Blache D. Impaired homocysteine metabolism and atherothrombotic disease. Lab Invest 2001; 81: 64572.
  • 14
    Esmon CT. Regulation of blood coagulation. Biochim Biophys Acta 2000; 1477: 34960.
  • 15
    Glaser BB, Morser J, Clarke JH, Blasko E, McLean K, Kuhn I, Chang RJ, Lin JH, Vilander L, Andrews WH, Light DR. Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. J Clin Invest 1992; 90: 256573.
  • 16
    Ishii H, Uchiyama H, Kazama M. Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost 1991; 65: 61823.
  • 17
    Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991; 88: 190614.
  • 18
    Davì G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, Patrono C. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990; 322: 176974.
  • 19
    Bauer KA, Kass BL, Beeler DL, Rosenberg RD. Detection of Protein C activation in humans. J Clin Invest 1984; 74: 203341.
  • 20
    Bauer KA, Weiss LM, Sparrow D, Vokonas PS, Rosenberg RD. Aging-associated changes in indices of thrombin generation and protein C activation in humans. J Clin Invest 1987; 80: 152734.
  • 21
    Fraker PJ, Speck JC. Protein and cell iodination with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenyl-glycoluril. Biochem. Biophys Res Commun 1978; 161: 84953.
  • 22
    De Cristofaro R, Rocca B, Marchioli R, Landolfi R. Plasma protein oxidation is associated with an increase of procoagulant markers causing an imbalance between pro- and anticoagulant pathways in healthy subjects. Thromb Haemost 2002; 87: 5867.
  • 23
    Espana F, Zuazu I, Vicente V, Estelles A, Marco P, Aznar J. Quantification of circulating activated protein C in human plasma by immunoassays-enzyme levels are proportional to total protein C levels. Thromb Haemost 1996; 75: 5661.
  • 24
    Oliver CN, Bong-whan A, Moerman EJ, Goldstein S, Stadtman ER. Age-related changes in oxidized proteins. J Biol Chem 1987; 262: 548891.
  • 25
    Wang Z, Ciabattoni G, Créminon C, Lawson J, FitzGerald GA, Patrono C, Maclouf J. Immunological characterization of urinary 8-epi-PGF excretion in man. J Pharmacol Exp Ther 1995; 275: 94100.
  • 26
    Ciabattoni G, Maclouf J, Catella F, FitzGerald GA, Patrono C. Radioimmunoassay of 11-dehydro-TXB2 in human plasma and urine. Biochim Biophys Acta 1987; 918: 2937.
  • 27
    Friedewald WT, Levy RI, Fredrickson DS. Estimation of plasma low density lipoprotein cholesterol concentration without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499502.
  • 28
    Hawkins CL, Davies M. Hypochlorite-induced oxidation of proteins in plasma. formation of chloramines and nitrogen-centred radicals and their role in protein fragmentation. Biochem J 1999; 340: 53948.
  • 29
    Stadtman ER. Oxidation of free amino acids and amino acid residues in proteins by radiolysis and by metal-catalyzed reactions. Annu Rev Biochem 1993; 62: 797821.
  • 30
    Stadtman ER. Protein oxidation and aging. Science 1992; 257: 12204.
  • 31
    Hanne HF, Refsgaard LT, Stadtman ER. Modifications of proteins by polyunsaturated fatty acid peroxidation products. Proc Natl Acad Sci USA 2000; 97: 6116.
  • 32
    Carr ME. Diabetes mellitus. A hypercoagulable state. J Diabetes Complications 2001; 15: 4454.
  • 33
    Takano S, Kimura S, Ohdama S, Aokin N. Plasma thrombomodulin in health and diseases. Blood 1990; 76: 20249.
  • 34
    Salomaa V, Matei C, Aleksic N, Sansores-Garcia L, Folsom AR, Juneja H, Chambless LE, Wu KK. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study. Lancet 1999; 353: 172934.
  • 35
    Welsh CH, Hassell KL, Badesch DB, Kressin DC, Marlar RA. Coagulation and fibrinolytic profiles in patient with severe pulmonary hypertension. Chest 1996; 110: 7107.
  • 36
    Sakamaki F, Kyotani S, Nagaya N, Sato N, Oya H, Satoh T, Nakanishi N. Increased plasma P-selectin and decreased thrombomodulin in pulmonary arterial hypertension were improved by continuous prostacyclin therapy. Circulation 2000; 102: 27205.
  • 37
    Hathaway CA, Heistad DD, Piegors DJ, Miller FJ Jr. Regression of atherosclerosis in monkeys reduces vascular superoxide levels. Circ Res 2002; 90: 27783.
  • 38
    Lentz SR, Miller FJ, Piegors DJ, Erger RA, Fernandez JA, Griffin JH, Heistad DD. Anticoagulant responses to thrombin are enhanced during regression of atherosclerosis in monkeys. Circulation 2002; 106: 8426.
  • 39
    Steinberg D, Witztum JL. Is the oxidative modification hypothesis relevant to human atherosclerosis? Circulation 2002; 105: 210711.
  • 40
    Sevanian A, Ursini F. Lipid peroxidation in membranes and low-density lipoproteins: similarities and differences. Free Radic Biol Med 2000; 29: 30611.
  • 41
    Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2001; 119: 39S63S.